SCHEMBL5124615

SCHEMBL5124615

CCOC(=O)c1ccc(CCSc2ccc3c(c2)C(=O)C(=O)N3C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.48
PABPC1 P11940 1/20 0.42
APOBEC3A P31941 1/20 0.42
EIF4H Q15056 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
MAPT P10636 1/20 0.40
PTPN1 P18031 1/20 0.40
PARK7 Q99497 1/20 0.39
KCNJ1 P48048 1/20 0.39
KCNH2 Q12809 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
ALDH1A1 P00352 2/20 0.38
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124521 0.86 PARK7 (0.44) MAPTPARK7MEN1KMT2AALDH1A1
SCHEMBL5118420 0.83 PARK7 (0.43) MAPTPTPN1PARK7KCNJ1KCNH2
SCHEMBL5117734 0.81 CES1 (0.43) MAPTPARK7MEN1KMT2AALDH1A1
SCHEMBL5125008 0.78 SMN1; SMN2 (0.38) MAPTKCNJ1KCNH2MEN1KMT2A
SCHEMBL5119292 0.78 PARK7 (0.46) CASP3MAPTPARK7MEN1KMT2A
SCHEMBL5126043 0.77 PARK7 (0.60) CASP3MAPTPARK7ALDH1A1LMNA
SCHEMBL5111486 0.77 PARK7 (0.44) CASP3MAPTPARK7MEN1KMT2A
SCHEMBL5114060 0.74 PARK7 (0.56) MAPTPARK7KMT2AALDH1A1
SCHEMBL5113902 0.73 PARK7 (0.55) MAPTPARK7MEN1KMT2AALDH1A1
SCHEMBL5117208 0.73 PARK7 (0.54) MAPTPARK7MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-03 US disclosed
EP-1828124-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2007-09-05 EP disclosed
WO-2006063863-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA CASP3 2895/4885PABPC1 3481/4885APOBEC3A 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.